MultiPoint Pacing™ Post Market Study

Any patient who received a market approved SJM Quadra Allure MP, Quadra Assura MP, or newer
SJM CRT MP device is eligible for enrollment in the study. MultiPoint Pacing (MPP)
programming guidance will be specified in the protocol. Patients will be followed for 12
months after implant. Data will be collected at Baseline (within 30 days prior to implant),
Post-Implant (within 30 days following successful CRT device implant), 3, 6, 12 months and
during any unscheduled follow-up visit.

Inclusion Criteria:

- Are scheduled to receive a new CRT implant or an upgrade from an existing implantable
cardioverter defibrillator or pacemaker implant (SJM CRT MP device and SJM Quadripolar
Lead) with no prior left ventricular lead placement

- Have the ability to provide informed consent for study participation and are willing
and able to comply with the prescribed follow-up tests and schedule of evaluations

Exclusion Criteria:

- Are expected to receive a heart transplant during the duration of the study

- Have an epicardial ventricular lead system (Active or Inactive)

- Are less than 18 years of age

- Are currently participating in a clinical investigation including an active treatment
arm and belong to the active arm

- Are not expected to complete the study follow-up schedule or duration due to any
health condition other than heart failure, such as malignancy, indication for heart
transplant or hospice care